Medical Imaging Analysis Software Developer Flonics Secures KRW 1 Billion in Seed Funding

Kakao Ventures, DHP, and Kangwon National University Technology Holdings Participate
Precise 3D Analysis of Blood Flow Dynamics Over Time
"Expecting to Revolutionize Efficiency in Clinical Practice"

Flonics, a medical imaging analysis software startup, announced on August 26 that it has secured seed investment from Kakao Ventures, Digital Healthcare Partners (DHP), and Kangwon National University Technology Holdings.

Flonics is developing the "Flonics-Streamliner," a solution that visualizes and analyzes blood flow movement in three dimensions over time. By precisely analyzing data such as blood flow patterns, speed, and direction in the heart and blood vessels, the software supports the diagnosis of cardiovascular and cerebrovascular diseases, as well as treatment planning and prognosis assessment.

Cardiovascular diseases are the leading cause of death worldwide, making accurate early diagnosis essential and requiring advanced analysis. Unlike conventional methods that interpret only the vascular shape from images, Flonics utilizes four-dimensional blood flow analysis technology to comprehensively understand the dynamic flow of blood as it changes moment by moment. This approach also helps detect subtle pathological changes that were previously difficult to identify. The blood flow analysis is completed within 30 minutes using a non-invasive method, thereby improving diagnostic efficiency. By directly incorporating feedback from medical professionals, the convenience for healthcare providers has also been maximized.

The Flonics team consists of CEO Ha Hojin, a leading expert in hemodynamics in Korea and a professor at the Department of Mechanical Biomedical and Mechatronics Engineering at Kangwon National University; Professor Yang Donghyun of the Department of Radiology at Asan Medical Center; and other experts in medical image processing and medical artificial intelligence. The team has been recognized for its exceptional capabilities in developing blood flow data research and treatment models, based on a deep understanding of the medical field and real clinical data. The company has also demonstrated its technological prowess and business potential by participating in several government projects, including the Ministry of Science and ICT’s Deep Science Startup Activation Initiative.

With this investment, Flonics plans to complete prototype development within this year and focus on further advancing its technology. At the same time, the company will validate clinical efficacy and continue collaborations with domestic and international partner institutions, including Asan Medical Center. By introducing a usage-based pricing model, Flonics aims to provide an economical alternative for hospitals and research institutions. Next year, the company plans to obtain regulatory approval in Korea and make a full-scale entry into the global market.

Jung Jooyeon, Senior Investment Manager at Kakao Ventures, who led the investment, stated, "With world-class blood flow analysis technology and medical AI capabilities, Flonics is a team that will lead the clinical application of four-dimensional blood flow analysis technology (4D Flow MRI). We will continue to support them so that their solution can help more patients in the field of cardiovascular disease diagnosis."

Ha Hojin, CEO of Flonics, said, "By successfully commercializing Flonics' innovative technology, we will create changes that both medical professionals and patients can experience, contributing to a more comfortable healthcare environment for everyone. From diagnosis to treatment of cardiovascular diseases, we aim to become the standard solution that medical professionals worldwide trust and choose first."

This content was produced with the assistance of AI translation services.